Rocket Lab reported record Q2 2026 results on August 10 after the close: $234.1 million in revenue, up 62% year over year and above the roughly $231 million analysts expected, plus a record $2.36 billion backlog. The stock still fell about 7% in the initial after-hours reaction on a wider per-share loss and renewed uncertainty about the Neutron rocket’s launch timeline, a reminder that a headline beat doesn’t guarantee a rally when a stock is already carrying this much event risk.
Key Takeaways
- Rocket Lab (RKLB) reported Q2 2026 revenue of $234.1 million, a company record, up 62% year over year and ahead of the roughly $231 million analyst consensus.
- The company posted a GAAP loss of $0.08 per share, including acquisition-related transaction costs tied to the pending Iridium deal, at the wider end of analyst estimates.
- Backlog reached a record $2.36 billion, up 137% year over year. Rocket Lab guided Q3 2026 revenue to $250 million to $265 million, which would be another record quarter if it holds.
- Despite the beat on revenue and backlog, RKLB fell roughly 7% in after-hours trading. CEO Peter Beck said Neutron is still targeted to reach the launchpad in Q4, but the window to complete its maiden flight within 2026 is narrowing, and that commentary weighed more heavily on the stock than the print itself.
- Every example below is hypothetical and illustrative only. Nothing here is a recommendation to buy, sell, or hold RKLB or any option on it.
What happened to RKLB since May
Rocket Lab hit an intraday all-time high of $151 on May 27, 2026 (closing at $150.23), riding a run of Space Force contract wins and a successful Synspective satellite launch. That high didn’t last. On June 29, Rocket Lab announced a definitive agreement to acquire Iridium Communications in a cash-and-stock deal valuing Iridium at approximately $8 billion, with Rocket Lab lining up a $3.6 billion bridge loan from Deutsche Bank and Wells Fargo to cover the cash portion. Iridium holders are set to receive $54 per share, and the deal targets a close in mid-2027, pending shareholder and regulatory approval.
The initial market reaction was positive. RKLB jumped into the mid-teens percentage-wise on announcement day, on the logic that combining launch, satellite manufacturing, and now a global communications constellation makes Rocket Lab a more vertically integrated space company. That reaction faded over the following weeks as investors weighed the dilution from a stock-and-cash deal this large against a two-year-plus integration timeline, and the stock slid to a low near $58 to $59 by late July. It recovered a meaningful portion of that drawdown, closing at $75.67 on August 6, going into the print still roughly 50% below its May peak.
That round trip, not the earnings print by itself, was the real story behind the market pricing such an elevated implied move heading into August 10. The market wasn’t just asking whether Rocket Lab beat estimates. It was still digesting whether the Iridium deal is value-accretive or a distraction, and that framing turned out to matter: the print beat, and the stock still fell.
What Wall Street priced in versus what actually happened
Heading into the print, consensus sat near $231 million in revenue and a per-share loss around $0.06. Rocket Lab beat on the top line, posting $234.1 million in revenue (product revenue of $181.3 million and service revenue of $52.7 million) and a record $2.36 billion backlog, up 137% year over year. The per-share loss of $0.08 came in wider than that headline consensus figure, weighed down in part by acquisition-related transaction costs tied to the pending Iridium deal.
The options market had priced an implied move near 17% heading into the print, well above RKLB’s own trailing four-quarter average of 10.4%. The stock’s actual initial after-hours move, roughly 7% lower, landed comfortably inside that priced-in range. What moved the stock wasn’t the revenue or backlog numbers, both of which beat, but CEO Peter Beck’s comments on the call: Neutron is still tracking to reach the launchpad in the fourth quarter, but the window to complete its maiden flight within 2026 is narrowing, raising the odds of a slip into 2027.
How to read an expected move like this one
The standard way to estimate an expected move is to take the price of the at-the-money straddle (the ATM call plus the ATM put, both expiring in the nearest weekly cycle after earnings) and divide it by the stock price. A hypothetical illustration: if RKLB is trading at $76 and the nearest weekly ATM straddle is priced around $13, that straddle price divided by the stock price works out to roughly 17%, close to how this event actually priced. This is illustrative math only. Anyone evaluating a similar setup on a different name should pull the live straddle price the morning of, or the afternoon before, the print, since it moves constantly as the stock and overall market volatility shift.
A strategy framework for a deal-overhang, high-IV name
None of what follows is a recommendation. It’s a framework for thinking about position sizing and structure when a stock is carrying both ordinary earnings risk and deal-related overhang risk at the same time, illustrated by how this specific setup played out.
- Defined-risk over undefined-risk. A name pricing a 17% move on a $76 stock was pricing roughly $13 of straddle premium. A trader selling premium there without a defined-risk structure, an iron condor or a credit spread rather than a naked short strangle, would have been exposed to the full post-earnings gap, which arrived from a source, the Neutron commentary, that had nothing to do with the reported numbers.
- Size for the worse of the two stories. A hypothetical trader sizing a position as if either the earnings miss or a negative Iridium or Neutron development could hit on the same day would have been positioned correctly here: the actual move came from launch-timeline commentary, not the earnings line items themselves.
- Watch for IV crush either way. With the print and call behind it, implied volatility on RKLB options is likely to compress sharply now that this event risk has cleared, the standard post-earnings pattern. A hypothetical long-premium position, a straddle or strangle bought ahead of the print, needed the roughly 7% realized move to beat that IV collapse, a much higher bar than simply being directionally right.
This event underscores why this setup wasn’t a clean, single-variable earnings bet. The stock beat on revenue and backlog and still fell, because the market was really trading Neutron’s timeline and the Iridium integration, not the quarter that just closed.
Choosing where to place the trade
A multi-leg structure like an iron condor involves opening and closing four separate contracts, so per-contract commissions compound quickly across brokers. Here’s how the major options-friendly brokers compare on a standard equity options order, verified as of 2026-08-06.
| Broker | Stock commission | Options, per contract (open) | Options, per contract (close) | Notes |
|---|---|---|---|---|
| Charles Schwab / thinkorswim | $0 | $0.65 | $0.65 | Full-featured thinkorswim platform, strong for chain analysis and probability tools. |
| tastytrade | $0 | $1.00 | $0.00 | Options-first platform; closing trades cost nothing, capped at $10 per leg on entry. |
| Interactive Brokers (IBKR Pro) | $0 | $0.65 | $0.65 | Rate applies at 10,000 contracts per month or fewer; falls at higher volume tiers. |
| Webull | $0 | $0.00 | $0.00 | No per-contract fee on single-stock options like RKLB (index options and very high order volume carry separate surcharges). |
For a four-leg structure like an iron condor around an event like this, that per-contract difference adds up across the open and the close. For options-focused execution with real-time Greeks and probability-of-touch tools built for exactly this kind of earnings-volatility setup, tastytrade is worth a look, particularly given the $0 closing cost on a strategy that’s designed to be closed early if it moves against you.
What actually moved the stock on the call
The revenue and backlog beats made headlines, but three things did more to move RKLB than the print itself:
- Neutron timeline commentary. CEO Peter Beck said Neutron is still targeted to reach the launchpad in the fourth quarter, but acknowledged the window to complete its maiden flight within 2026 is narrowing. That raised the odds, in investors’ eyes, of a slip into 2027, and it was the single biggest driver of the after-hours decline.
- Iridium integration commentary. The deal remains the dominant open question for the stock; specifics on financing terms, regulatory timeline, or synergies (or the lack of new detail) continue to matter more than any single quarter’s numbers.
- Record backlog and Q3 guidance. The $2.36 billion backlog, up 137% year over year, and Q3 guidance of $250 million to $265 million point to continued growth in Rocket Lab’s launch and Space Systems businesses, even though that strength wasn’t what the market focused on this time.
Bottom Line
RKLB’s Q2 2026 print beat on revenue and backlog, yet the stock still fell about 7% after hours, inside the roughly 17% move the options market had priced in. The gap between a beat and a decline came down to CEO commentary narrowing the Neutron rocket’s 2026 launch window, not the earnings line items themselves. It’s a useful case study in how, when a stock carries deal-integration risk on top of ordinary earnings uncertainty, the call itself can move the stock more than the headline numbers.
FAQ
Q: When did Rocket Lab report Q2 2026 earnings?
A: Monday, August 10, 2026, after market close, as the company had announced in advance.
Q: What were Rocket Lab’s actual Q2 2026 results?
A: Record revenue of $234.1 million, up 62% year over year and above the roughly $231 million consensus, and a GAAP loss of $0.08 per share. Backlog reached a record $2.36 billion, up 137% year over year, and Rocket Lab guided Q3 2026 revenue to $250 million to $265 million.
Q: How did RKLB stock react to the print?
A: The stock fell roughly 7% in the initial after-hours reaction despite beating on revenue and backlog. CEO Peter Beck’s comments narrowing the window for Neutron’s 2026 maiden launch weighed more heavily than the reported numbers.
Q: How did the actual move compare to what options were pricing?
A: Options had priced an implied move near 17% heading into the print, above RKLB’s own trailing four-quarter average of 10.4%. The roughly 7% after-hours move landed comfortably inside that priced-in range, consistent with the print carrying real, but not maximal, event risk.
Q: What happens to RKLB options if the Iridium deal falls through?
A: If a pending acquisition is terminated, the target’s stock, Iridium in this case, typically falls back toward pre-announcement levels. For the acquirer, Rocket Lab, a broken deal would likely remove the associated financing and dilution overhang, which could cut both ways for the stock depending on how the market weighs the lost strategic rationale against reduced near-term risk. Standard options contracts on RKLB itself are not directly adjusted by the Iridium deal’s outcome, since RKLB is the acquirer, not the target.
Q: Was selling premium into this print a good idea, in hindsight?
A: That still depends entirely on individual risk tolerance and account size, and this article isn’t a recommendation either way. What this event illustrated is that this setup carried two sources of uncertainty stacked together, earnings and deal-integration risk, which argues for defined-risk structures and conservative sizing over an undefined-risk short strangle, regardless of how attractive the premium looked beforehand.
Keep learning: for another newly volatile space-sector name that just reported its own first quarter as a changed company, see our SpaceX (SPCX) Q2 2026 earnings recap.